Literature DB >> 11082147

Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia.

A S Wierzbicki1, M Lambert-Hammill, P J Lumb, M A Crook.   

Abstract

The role of renin-angiotensin system polymorphisms as risk factors for coronary heart disease (CHD) is controversial. This study investigated their role in patients with heterozygous familial hypercholesterolemia (FH). Polymorphism frequencies for angiotensin-I-converting enzyme insertion/deletion (ACE I/D), angiotensinogen M235T, and angiotensin-II type I receptor (AG2R) A1166C were determined in 112 patients with FH and 72 patients with polygenic hypercholesterolemia, of whom 26.7% and 41.6%, respectively, had established CHD. None of the polymorphisms were associated with risk of CHD in patients with polygenic hypercholesterolemia in this study. Logistic regression analysis of risk factors for CHD in patients with FH identified male sex (odds ratio [OR]=3.03; 95% CI, 3.07 to 3.72; P=0.05), smoking (OR=2.91; 95% CI, 2.16 to 4.24; P=0.05), diastolic blood pressure (OR=3.70; 95% CI, 3.43 to 3.97; P=0.02), plasma glucose (OR=3.31; 95% CI, 3. 10 to 3.52; P=0.04), and the AG2R A1166C polymorphism as risk factors. The OR for the AG2R A1166C polymorphism was 2.26 (95% CI, 1.26 to 3.72; P=0.06) and increased to 3.10 (95% CI, 1.20 to 7.52; P=0.04) after adjustment for other risk factors. The AG2R A1166C polymorphism may interact with severe hypercholesterolemia and other risk factors to increase risk of CHD in FH patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082147     DOI: 10.1161/01.hyp.36.5.808

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Angiotensin II type I receptor gene polymorphism: anthropometric and metabolic syndrome traits.

Authors:  M R Abdollahi; T R Gaunt; H E Syddall; C Cooper; D I W Phillips; S Ye; I N M Day
Journal:  J Med Genet       Date:  2005-05       Impact factor: 6.318

Review 3.  Angiotensin II receptors and drug discovery in cardiovascular disease.

Authors:  Chiranjib Dasgupta; Lubo Zhang
Journal:  Drug Discov Today       Date:  2010-12-13       Impact factor: 7.851

4.  The M235T polymorphism in the AGT gene and CHD risk: evidence of a Hardy-Weinberg equilibrium violation and publication bias in a meta-analysis.

Authors:  Mohammad Hadi Zafarmand; Yvonne T van der Schouw; Diederick E Grobbee; Peter W de Leeuw; Michiel L Bots
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

Review 5.  Clinical Aspects of Genetic and Non-Genetic Cardiovascular Risk Factors in Familial Hypercholesterolemia.

Authors:  Eszter Berta; Noémi Zsíros; Miklós Bodor; István Balogh; Hajnalka Lőrincz; György Paragh; Mariann Harangi
Journal:  Genes (Basel)       Date:  2022-06-27       Impact factor: 4.141

6.  Association of angiotensin converting enzyme gene insertion/deletion polymorphism and familial hypercholesterolemia in the Saudi population.

Authors:  Khalid K Alharbi; Tarek S Kashour; Wejdan Al-Hussaini; May Salem Al-Nbaheen; Sarar Mohamed; Rana M W Hasanato; Waleed Tamimi; Mohammed Yahya Al-Naami; Imran Ali Khan
Journal:  Lipids Health Dis       Date:  2013-12-01       Impact factor: 3.876

Review 7.  Antibodies against Angiotensin II Type 1 and Endothelin 1 Type A Receptors in Cardiovascular Pathologies.

Authors:  Giovanni Civieri; Laura Iop; Francesco Tona
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.